Patient Characteristics and Comparisons of Nodal SUVmax According to Clinicopathologic Parameters
| Characteristic | No. of patients (%) | Nodal SUVmax* (mean ± SD) | P |
| T stage† | 0.043 | ||
| T1 | 29 (44.6) | 1.8 ± 1.6 | |
| T2 | 29 (44.6) | 2.9 ± 2.8 | |
| T3 | 4 (6.2) | 4.9 ± 2.3 | |
| T4 | 3 (4.6) | 3.5 ± 2.3 | |
| ER | 0.0011 | ||
| Positive‡ | 48 (73.8) | 2.0 ± 1.9 | |
| Negative | 17 (26.2) | 4.1 ± 2.8 | |
| PR | 0.0046 | ||
| Positive‡ | 46 (70.8) | 2.0 ± 1.9 | |
| Negative | 19 (29.2) | 3.8 ± 3.1 | |
| HER2§ | 0.5544 | ||
| Positive║ | 20 (30.8) | 2.8 ± 3.0 | |
| Negative | 45 (69.2) | 2.4 ± 2.0 | |
| N stage† | 0.003 | ||
| N1 | 40 (61.5) | 1.8 ± 1.8 | |
| N2 | 16 (24.6) | 3.2 ± 2.2 | |
| N3 | 9 (13.8) | 4.5 ± 3.4 | |
| Stage† | 0.011 | ||
| II | 36 (55.4) | 1.9 ± 1.9 | |
| III | 29 (44.6) | 3.3 ± 2.6 | |
| Disease group | <0.0001 | ||
| Disease-free | 53 (81.5) | 1.9 ± 1.9 | |
| Recurrence | 12 (18.5) | 5.2 ± 2.3 |
↵* SUVmax of axillary LN.
↵† Staging system of American Joint Committee on Cancer (seventh edition).
↵‡ According to immunohistochemical staining for ER/PR.
↵§ Human epidermal growth factor receptor 2.
↵║ Immunohistochemical 3+ or, in case of immunohistochemical 2+, positive on fluorescence in situ hybridization for HER2 gene amplification.